InMed Pharmaceuticals Inc.
Develops cannabinoid-based drugs and manufactures rare cannabinoids for B2B markets.
INM | US
Overview
Corporate Details
- ISIN(s):
- CA4576375022
- LEI:
- Country:
- United States of America
- Address:
- 1445-885 WEST GEORGIA ST., VANCOUVER
- Website:
- https://www.inmedpharma.com/
- Sector:
- Manufacturing
Description
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that target the CB1 and CB2 cannabinoid receptors. The company's therapeutic pipeline includes preclinical programs for Alzheimer's disease (INM-901) and dry age-related macular degeneration (INM-089). In dermatology, InMed has completed a Phase 2 clinical trial for the treatment of epidermolysis bullosa. Additionally, its subsidiary, BayMedica, manufactures and supplies high-purity, rare cannabinoids such as cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), and cannabidivarin (CBDV) as raw ingredients for the business-to-business health and wellness market.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all InMed Pharmaceuticals Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for InMed Pharmaceuticals Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for InMed Pharmaceuticals Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
